ETFs Are Net Sellers of Gilead Sciences (GILD) on Oct. 23

This article first appeared on GuruFocus.

AVLV drove the day’s ETF activity in Gilead Sciences (GILD), cutting its position by $28.3 million as ETFs sold a net $30.4 million of the stock on Friday, Oct. 23. More funds traded the other way, with 29 ETFs buying versus 14 selling, but the sellers moved larger amounts. The net selling extended a four-day streak, following $2.8 million on Oct. 22, $17.0 million on Oct. 21 and $19.3 million on Oct. 20. The run reversed course from Oct. 19, when ETFs bought a net $58.2 million.

See all ETF and guru trades in GILD on its GILD guru trades page.

Which ETFs sold GILD on Friday?

The largest sellers by dollar value were AVLV ($28.3 million), SPY ($10.5 million) and XLV ($7.5 million). In all, 29 ETFs added shares and 14 cut them.

AVLV accounted for the bulk of the selling with a $28.3 million reduction, leaving it with no shares held. SPY trimmed $10.5 million while holding 15,190,415 shares, and XLV sold $7.5 million, retaining 8,903,786 shares at a 2.98% weight. IBB cut $2.7 million and still holds 5,878,634 shares, the largest weight among the top movers at 8.58%. Smaller reductions came from USMV, DVY, IYH and SPYG. Gilead sits in the Healthcare sector, in the Drug Manufacturers – General industry, with a market cap of $196.8 billion.

Have ETFs been buying or selling GILD lately?

Over the last 5 reported days, ETFs were net buyers on 1 and net sellers on 4, so the recent trend is mostly selling.

What does GILD do?

Gilead Sciences is a biopharmaceutical company best known for its antiviral franchises. It dominates HIV treatment and prevention with Biktarvy, the world’s leading HIV regimen, and Descovy, and launched lenacapavir (Yeztugo), a twice-yearly injectable for HIV prevention regarded as a breakthrough in the field.

Gilead Sciences reported trailing-12-month revenue of $30.54 billion, up 6.5% over one year, with a gross margin of 79.7% and a net margin of -10.6%. The stock trades at a P/B of 16.65 and a P/S of 6.5, with a market cap of $196.8 billion. Its GF Score is 73 and GF Value of $107.28 compares with a price of $158.69. The dividend yield is 2.18%, and the shares have returned 31.62% year to date.